SCHEMBL13671200

SCHEMBL13671200

CB(O)N1CC(C(=O)O)C(c2ccccc2)C1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ SLC6A2 P23975 2/20 0.40
▸ SLC6A4 P31645 2/20 0.40
▸ SLC6A3 Q01959 2/20 0.40
▸ FFAR1 O14842 1/20 0.39
▸ TLR2 O60603 2/20 0.39
▸ TLR1 Q15399 2/20 0.39
▸ HDAC4 P56524 1/20 0.38
▸ MCL1 Q07820 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ HRH3 Q9Y5N1 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13041171 1.00 MEN1 (0.42) MEN1KMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL12592372 0.87 SLC6A2 (0.49) SLC6A2SLC6A4SLC6A3HRH3
SCHEMBL13473846 0.87 SLC6A2 (0.49) SLC6A2SLC6A4SLC6A3HRH3
SCHEMBL14371524 0.87 SLC6A2 (0.49) SLC6A2SLC6A4SLC6A3HRH3
SCHEMBL12592377 0.87 SLC6A2 (0.49) SLC6A2SLC6A4SLC6A3HRH3
SCHEMBL14065595 0.87 SLC6A2 (0.43) MEN1KMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL14065597 0.87 SLC6A2 (0.43) MEN1KMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL13041172 0.85 SLC6A3 (0.58) SLC6A2SLC6A4SLC6A3TLR2TLR1
SCHEMBL13041182 0.81 BACE1 (0.38) SLC6A2SLC6A4SLC6A3HDAC4SMN1; SMN2
SCHEMBL13525552 0.77 MEN1 (0.64) MEN1KMT2ASLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253744-A1 Acylated piperidine derivatives as melanocortin-4 receptor modulators MERCK SHARP & DOHME CORP. 2009-10-08 — — US disclosed
US-7419990-B2 Piperidine derivatives as melanocortin-4 receptor agonists MERCK & CO., INC. (US) 2008-09-02 — — US disclosed
US-7329673-B2 Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists MERCK & CO., INC. (US) 2008-02-12 — — US disclosed
US-7276520-B2 Bicyclic piperidine derivatives as melanocortin-4 receptor agonists MERCK & CO., INC. (US) 2007-10-02 — — US disclosed
US-7160886-B2 Acylated piperazine derivatives as melanocortin-4 receptor agonists MERCK & CO., INC. (US) 2007-01-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253744-A1 Acylated piperidine derivatives as melanocortin-4 receptor modulators MC4R, MC5R, MC3R MEN1 2383/4885KMT2A 914/4885SLC6A2 373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback